Undervalued, Oversold, Overlooked: MRK Hits The Key Zone!Hi all,
Merck & Co. (MRK) is a global pharmaceutical titan and is currently trading near its 52-week low of ~$79. Anchored by Keytruda’s 7% YoY revenue growth, a stable ~4% dividend yield, and an average fair value estimate of $156.59 (98% upside), MRK appears significantly undervalued.
Analysts f
